Sector
HealthcareOpen
₹625Prev. Close
₹627.25Turnover(Lac.)
₹7,360.61Day's High
₹636Day's Low
₹624.3552 Week's High
₹960.652 Week's Low
₹599.55Book Value
₹115.66Face Value
₹10Mkt Cap (₹ Cr.)
25,433.54P/E
57.35EPS
11.02Divi. Yield
0.28 Apr 2025
12:00 AM
Board Meeting
Agenda : Audited Result
24 Apr 2024
12:00 AM
AGM
Announcement Date: 24 Apr, 2024
The outcome of the inspection has been classified as “Voluntary Action Indicated” or VAI.
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 402 | 401.4 | 400.8 | 400 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,789.5 | 3,217.5 | 2,891.2 | 2,418.3 |
Net Worth | 4,191.5 | 3,618.9 | 3,292 | 2,818.3 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 2,601.4 | 2,179.4 | 2,011.9 | 1,423.1 |
yoy growth (%) | 19.36 | 8.32 | 41.37 | 18.5 |
Raw materials | -749 | -526.5 | -519.4 | -381.7 |
As % of sales | 28.79 | 24.15 | 25.81 | 26.82 |
Employee costs | -697.8 | -641.5 | -572.2 | -376.9 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 512.4 | 432.4 | 444.4 | 372.1 |
Depreciation | -309.7 | -274.5 | -219.3 | -131.4 |
Tax paid | -87.9 | -63.7 | -104.2 | -67 |
Working capital | -34.39 | 497.9 | -955.5 | 480.2 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.36 | 8.32 | 41.37 | 18.5 |
Op profit growth | 18.41 | 8.64 | 57.92 | 1.5 |
EBIT growth | 16.6 | -3.94 | 21.32 | 8.46 |
Net profit growth | -2.45 | -1.89 | 34.87 | 6.19 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 3,642.4 | 3,488.6 | 3,192.9 | 2,604.2 | 2,184.3 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,642.4 | 3,488.6 | 3,192.9 | 2,604.2 | 2,184.3 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 103.8 | 90.6 | 70.9 | 52.8 | 99.6 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Max Healthcare Institute Ltd MAXHEALTH | 1,163 | 149.54 | 1,12,953.74 | 177.39 | 0.13 | 658.7 | 85.26 |
Apollo Hospitals Enterprise Ltd APOLLOHOSP | 7,009.5 | 77.73 | 1,00,772.2 | 333.4 | 0.4 | 2,075.3 | 607.44 |
Fortis Healthcare Ltd FORTIS | 748.1 | 440.26 | 56,504.84 | -42.23 | 0.13 | 388.47 | 120.19 |
Narayana Hrudayalaya Ltd NH | 1,873.8 | 88.69 | 38,244.08 | 159.98 | 0.24 | 919.03 | 106.95 |
Global Health Ltd MEDANTA | 1,163 | 62.66 | 31,236.71 | 93.41 | 0.04 | 802.87 | 130.22 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson
Kiran Mazumdar Shaw
Non Executive Director
Catherine Patricia Rosenberg
Independent Director
Paul Frederick Blackburn
Independent Director
Vijay Kuchroo
Managing Director & CEO
Jonathan Hunt
Lead Independent Director
Vinita Bali
Company Sec. & Compli. Officer
Priyadarshnini Mahapatra
Independent Director
Sharmila Karve
Independent Director
Kush Parmar
Executive Director & CFO
SIBAJI BISWAS
Independent Director
Nilanjan Roy
Independent Director
Manja Boerman
Biocon SEZ Biocon Park,
Plot No 2 & 3 Bommasandra Inds,
Karnataka - 560099
Tel: 91-80-68915000/67758781
Website: http://www.syngeneintl.com
Email: investor@syngeneintl.com; Mayank.Verma@syngeneintl
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and ...
Read More
Reports by Syngene International Ltd
What is the Syngene International Ltd share price today?
What is the Market Cap of Syngene International Ltd?
What is the PE and PB ratio of Syngene International Ltd?
What is the 52 Week High and Low of Syngene International Ltd?
What is the CAGR of Syngene International Ltd?
What is the shareholding pattern of Syngene International Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
